Medicenna Therapeutics Corp. (MDNA.TO) Deep Dive Video
Summary
Medicenna’s differentiated IL-2 Superkine data and near-term oncology catalysts create substantial upside optionality, but a short cash runway and dependence on clinical success and partnerships make MDNA a highly speculative investment.